Another example is the successful engineering of cytokine-inducible SH2-containing protein (CIS) deletion in human primary NK cells using CRISPR/Cas9, which significantly enhances NK cell-mediated anti-tumor effects, particularly in GBM [65]. The gene discussed is CISH; the disease is glioblastoma.